News & Views
IT Solutions Focus
Oct 26 2007
Author: Kim Shah, Thermo Fisher Scientific and Ajit Nagral, Megaware Inc. on behalf of Unassigned Independent Article
Rapid market growth in generic drug manufacture is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA (Abbreviated New Drug Application) guidelines. Bioequivalence studies are a critical component of ANDA submissions. The purpose of these studies is to demonstrate pharmaceutical equivalence between a generic drug product and the corresponding reference listed drug. Establishing bioequivalence allows for a regulatory conclusion of therapeutic equivalence [1]. According to IMS Health, global generics sales are increasing by 19% per year [2]. A generic is the bioequivalent of an original pharmaceutical product, whose patent has expired. Generics are much cheaper to produce than the original brand on which they are based. Once a product has lost patent protection, it is replaced almost entirely within six to twelve months by generics, which are sold at 85% to 90% less than the original products [3]. This compression of the time-to-market for generics, and the extreme price sensitivity of final generic drugs means that speed and cost are major drivers for customers. The urgency to remove stages from the manufacturing process of generic drugs is more compelling than ever in order to ensure improved throughput and much easier regulatory compliance.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark